BioPharmSignal logoBioPharmSignal

Biotech News

Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology

Novan (NOVN)NovanFDA / regulatory

- Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum -

- Currently no FDA-approved prescription therapies for...

Related news

NOVNNovan2023-01-06 08:00 EST

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

NOVNNovan2023-03-07 08:00 EST

FDA Accepts Novan's NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

View all latest news

Novan

Novan was a dermatology-focused biotechnology company built around nitric oxide-based therapies for skin conditions and related inflammatory indications. Its story was centered on a narrow clinical platform and the challenge of turning topical science into a durable commercial path.

Recent company news

NOVNNovan2023-07-17 08:45 EST

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

NOVNNovan2023-06-05 09:00 EST

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

NOVNNovan2023-05-31 16:05 EST

Novan Focuses Strategic Direction and Announces Restructuring

NOVNNovan2023-05-15 06:45 EST

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

NOVNNovan2023-05-08 09:05 EST

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States